Doctors provide new hope for pancreatic cancer patients with less invasive radiofrequency ablation

UT Health San Antonio Multispecialty and Research Hospital became the first in South Texas to use an emerging and ...

IceCure's ProSense(R) Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense (R) ...
TipRanks on MSN

IceCure’s ProSense® cryoablation gains recognition at RSNA 2025

Icecure Medical ( ($ICCM) ) just unveiled an update. On December 10, 2025, IceCure Medical announced that its ProSense® Cryoablation technology ...

Glut1 protein may be a potential therapeutic target for kidney disease

Targeting and disabling a certain protein essential to transporting glucose properly through cells (Glucose Transporter 1, or ...
Malaysian Reserve

IceCure’s ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

This latest approval further broadens global access to ProSense® and supports IceCure’s commercial momentum following the U.S. Food and Drug Administration’s (“FDA”) recent marketing authorization of ...
urologytimes

FDA updates in urology: September 2025

Johnson & Johnson's gemcitabine intravesical system approved for BCG-unresponsive NMIBC, showing an 82% complete response rate in the SunRISe-1 trial. Medtronic's Altaviva device approved for urge ...
KRQE Blogs

Techsomed Receives FDA 510(k) Clearance Expanding BioTraceIO360 Platform to Kidney Ablation Advancing a Unified Multi-Organ Image-Guided Therapy Platform

TEL AVIV, Israel, Sept. 22, 2025 /PRNewswire/ -- Techsomed, a leader in AI-Driven Precision for Image-Guided Care, today announces U.S. FDA 510 (k) clearance expanding indications for BioTraceIO360* ...